{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:16:20Z","timestamp":1769732180258,"version":"3.49.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1136\/annrheumdis-2013-204577","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T03:37:11Z","timestamp":1389152231000},"page":"516-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"title":["Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis"],"prefix":"10.1016","volume":"73","author":[{"given":"Jackie L","family":"Nam","sequence":"first","affiliation":[]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[]},{"given":"Cecile","family":"Gaujoux-Viala","sequence":"additional","affiliation":[]},{"given":"Kaoru","family":"Takase","sequence":"additional","affiliation":[]},{"given":"Mario","family":"Leon-Garcia","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Landewe","sequence":"additional","affiliation":[]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[]},{"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2013-204577_bib1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/ard.2009.126748","article-title":"Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Knevel","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","article-title":"The role of biosimilars in the treatment of rheumatic diseases","volume":"72","author":"Dorner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib5","doi-asserted-by":"crossref","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs\u20142013 update. Ann Rheum Dis 2014;73:492\u2013509.","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"10.1136\/annrheumdis-2013-204577_bib6","doi-asserted-by":"crossref","unstructured":"Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a New Nomenclature of Disease Modifying Antirheumatic Drugs. Ann Rheum Dis 2014;73:3\u20135.","DOI":"10.1136\/annrheumdis-2013-204317"},{"key":"10.1136\/annrheumdis-2013-204577_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib8","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib9","series-title":"The Cochrane Collaboration","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1136\/annrheumdis-2013-204577_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1136\/annrheumdis-2013-204577_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer"},{"key":"10.1136\/annrheumdis-2013-204577_bib13","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204577_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/s10165-010-0324-4","article-title":"Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: A randomized trial","volume":"20","author":"Kameda","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204577_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","article-title":"Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial","volume":"374","author":"van Vollenhoven","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-204577_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.1221","article-title":"A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study","author":"Heimans","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib18","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O'Dell","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2013-204577_bib20","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.23733","article-title":"The importance of reporting disease activity states in rheumatoid arthritis clinical trials","volume":"58","author":"Aletaha","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","article-title":"Induction therapy with adalimumab plus methotrexate for 24\u2005weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study","volume":"72","author":"Detert","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2013-eular.246","article-title":"Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients (pts) with early rheumatoid arthiritis (RA): clinical and radiographic outcomes from a randomised, placebo-controlled trial","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10067-010-1654-5","article-title":"Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis","volume":"30","author":"Bao","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204577_bib26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/ker519","article-title":"Certolizumab pegol plus MTX administered every 4\u2005weeks is effective in patients with RA who are partial responders to MTX","volume":"51","author":"Choy","year":"2012","journal-title":"Rheumatol UK"},{"key":"10.1136\/annrheumdis-2013-204577_bib27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/annrheumdis-2012-eular.501","article-title":"Efficacy and safety of certolizumab pegol (CZP) with concomitant methotrexate (MTX) in Korean rheumatoid arthritis (RA) patients (pts) with an inadequate response to MTX","volume":"71","author":"Kang","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/art.27348","article-title":"Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study","volume":"62","author":"Kremer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib29","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2011.200317","article-title":"Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: Results of the GO-FORTH study","volume":"71","author":"Tanaka","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/annrheumdis-2013-eular.1338","article-title":"Safety and efficacy of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite MTX therapy: results from a randomized, placebo-controlled, phase 3 trial","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2013-eular.746","article-title":"Intravenous golimumab inhibits radiographic progression and maintains clinical efficacy and safety in patients with active rheumatoid arthritis despite methotrexate therapy: 1-year results of a phase 3 trial","volume":"72","author":"Weinblatt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib32","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2013-204577_bib33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-204577_bib34","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib35","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/annrheumdis-2011-200490","article-title":"Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis","volume":"71","author":"Schoels","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib37","article-title":"Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Week 28 results from a phase IIIB randomized controlled study","volume":"1","author":"Weinblatt","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib38","first-page":"665","article-title":"New provisional American College of Rheumatology and European League Against Rheumatism remission criteria: results from 2 randomized, controlled golimumab trials in patients with rheumatoid arthritis","volume":"71(Suppl 3)","author":"Emery","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.30263","article-title":"The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy","volume":"63","author":"Emery","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib40","first-page":"420","article-title":"Goluimumab, a human anti-TNF\u03b1 monoclonal antibody administered subcutaneously every four weeks as monotherapy in patients with acitve rheumatoid arthritis despite DMARD therapy:24-week results fo clinical and radiographic assessments","volume":"70","author":"Takeuchi","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-204577_bib43","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib44","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/ard.2005.043299","article-title":"Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study","volume":"65","author":"van Riel","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib45","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2006.068585","article-title":"Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial","volume":"67","author":"van Riel","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib46","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3899\/jrheum.110014","article-title":"Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-Week results from the JESMR study","volume":"38","author":"Kameda","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204577_bib47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-eular.245","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study)","volume":"72","author":"Takeuchi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2012-eular.2058","article-title":"Clinical, radiographic, and immunogenic effects after 1\u2005year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: the ACT-RAY study","volume":"71","author":"Dougados","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.27268","article-title":"Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study","volume":"62","author":"Emery","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib51","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-204577_bib52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2012-201365","article-title":"Infliximab for 6\u2005months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)","volume":"72","author":"Leirisalo-Repo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib53","author":"Horslev-Petersen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib54","doi-asserted-by":"crossref","unstructured":"Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 2014;73:75\u201385.","DOI":"10.1136\/annrheumdis-2013-203440"},{"key":"10.1136\/annrheumdis-2013-204577_bib55","article-title":"Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks as monotherapy in patients with active rheumatoid arthritis despite DMARD therapy: 52-week results of clinical, radiographic and pharmacokinetic assessments","volume":"1","author":"Takeuchi","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib56","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib57","first-page":"S177","article-title":"Preliminary results of a multicentre randomised controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis","volume":"63","author":"Villeneuve","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib58","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ker355","article-title":"Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial","volume":"51","author":"van Eijk","year":"2012","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-204577_bib59","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2012-eular.3069","article-title":"Efficacy of addition, or continuation, of adalimumab in patients who did not achieve stable low disease activity with methotrexate or adalimumab plus methotrexate in the OPTIMA study","volume":"71","author":"Kavanaugh","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib60","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","article-title":"Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 Year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"Van Vollenhoven","year":"2012","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-204577_bib61","first-page":"S335","article-title":"Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib62","first-page":"259","article-title":"The OPTIMA study of methotrexate and adalimumab: 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26\u2005weeks","volume":"70","author":"Smolen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib63","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/ard.2008.093294","article-title":"Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis","volume":"68","author":"van der Kooij","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib64","article-title":"Eight year results of disease activity steered treatment in a large recent rheumatoid arthritis cohort: Clinical and radiological outcomes","volume":"1","author":"Dirven","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib65","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/annrheumdis-2013-eular.740","article-title":"Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomised, controlled study on early rheumatoid arthritis","volume":"72(Suppl 3)","author":"H\u00f8rslev-Petersen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib66","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/ard.2008.092254","article-title":"Drug-free remission, functioning and radiographic damage after 4\u2005years of response-driven treatment in patients with recent-onset rheumatoid arthritis","volume":"68","author":"Van Der Kooij","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib67","article-title":"Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: Results of a phase 4, double-blind, placebo-controlled trial","volume":"1","author":"Kavanaugh","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib68","first-page":"399","article-title":"Assessing maintenance of reimssion with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthirtis who achieved remission with etanercept and methotrexate: the PRIZE study","volume":"72","author":"Emery","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib69","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2013-204577_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2013-eular.247","article-title":"Clinical and radiographic outcomes at two years and the effect of tocilizumab (TCZ) discontinuation following sustained remission in the second year of the ACT-RAY study","volume":"72","author":"Huizinga","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib71","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/annrheumdis-2012-eular.2607","article-title":"Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the CERTAIN study","volume":"71","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib72","first-page":"4169","article-title":"Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial","volume":"64","author":"Fautrel","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib73","first-page":"4171","volume":"64","author":"van Vollenhoven","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204577_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/annrheumdis-2013-eular.273","article-title":"A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54\u2005week results from the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib76","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2013-204577_bib77","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/rheumatology\/kes274","article-title":"Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial","volume":"52","author":"Fleischmann","year":"2013","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-204577_bib78","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2012-eular.3081","article-title":"Biologic free disease control (BFDC) in early RA: predictors of successful withdrawal of adalimumab (ADA) after achieving stable low disease activitiy with ADA plus methotrexate (MTX) -data from the OPTIMA study","volume":"71","author":"Smolen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib79","first-page":"262","article-title":"Maintenance of biologic-free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotrexate","volume":"70","author":"Emery","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib80","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2013-eular.632","article-title":"Nonclinical assessments demonstrating the similarity of the proposed biosimilar PF-05280586 and rituximab","volume":"72","author":"Hurst","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib81","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2013-eular.736","article-title":"Comparative, randomized, simple blind to evaluate efficacy and safety of Infinitam (etanercept), associated with methotrexate compared with Enbrel (etanercept) associated with methotrexate in patients with moderate and severe rheumatoid arthritis","volume":"72","author":"Moctezuma","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib82","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs\u2014a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib83","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2013-204588","article-title":"Efficacy of conventional synthetic DMARDs, glucocorticoids and tofacitinib\u2014a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Gaujoux-Viala","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib84","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib85","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/ard.2010.147751","article-title":"Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: Subanalysis of the BeSt study","volume":"70","author":"Van Den Broek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib86","first-page":"259","article-title":"Efficacy and safety of certolizumab pegol after incomplete response to DMARDS in RA patients with low moderate disease activity: results from CERTAIN, a phase IIIB study","volume":"70","author":"Smolen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib87","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/annrheumdis-2013-eular.708","article-title":"Impact of progressive spacing of TNF-blocker injections on signs and symptoms of rheumatoid arthritis patients in DAS28 remission: the STRASS randomized controled trial","volume":"72","author":"Fautrel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib88","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/annrheumdis-2013-eular.271","article-title":"Targeting the lowest efficacious dose for rheumatoid arthiritis patients in remission: clinical and structural impact of a step-down strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial)","volume":"72","author":"Fautrel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204577_bib89","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/annrheumdis-2013-eular.1312","article-title":"In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50\u2005mg or 25\u2005mg weekly are both clinically superior to discontinuation: results frum a randomized, 3-arm, double-blind study","volume":"72","author":"Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1136\/annrheumdis-2013-204577corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724211572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724211572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2013-204577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:31:29Z","timestamp":1737250289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724211572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0003496724211572"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-204577","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-204577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-204573","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}